Results 81 to 90 of about 7,548 (263)
BMC Endocrine Disorders, 2023 Background Two types of fixed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist (GLP-1RA) have been approved for use in type 2 diabetes.
Ivona Risovic +3 more
doaj +1 more source
Recombinant Human Insulin in Global Diabetes Management – Focus on Clinical Efficacy [PDF]
, 2017 Biosynthetic human insulin and insulin analogues are the mainstay of insulin therapy for both type 1 and type 2 diabetes although access to human insulin at affordable prices remains a global issue.
Landgraf, Wolfgang +3 more
core +1 more source
Assessment of thyroid cancer risk associated with glucagon‐like peptide 1 receptor agonist use
Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1499-1507, February 2026.Abstract Aims Published literature has raised concerns regarding a causal association between glucagon‐like peptide 1 receptor agonist (GLP‐1RA) use and thyroid cancer risk in adults. In this analysis, we evaluated the association between thyroid cancer risk and GLP‐1RA use.
Tina Vilsbøll +8 more
wiley +1 more source
Clinical use of insulin degludec
Diabetes Research and Clinical Practice, 2015 The limitations of current basal insulin preparations include concerns related to their pharmacokinetic and pharmacodynamic properties, hypoglycaemia, weight gain, and perception of management complexity, including rigid dosing schedules. Insulin degludec (IDeg) is a novel basal insulin with improved pharmacokinetic and pharmacodynamic properties ...
Vora, Jiten +8 more
openaire +2 more sources
Patient-level meta-analysis of the EDITION 1, 2 and 3 studies : glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes [PDF]
, 2015 AimsTo conduct a patient-level meta-analysis of the EDITION 1, 2 and 3 studies, which compared the efficacy and safety of new insulin glargine 300 U/ml (Gla-300) with insulin glargine 100 U/ml (Gla-100) in people with type 2 diabetes (T2DM) on basal and ...
Bolli, G. B. +6 more
core +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1304-1314, February 2026.Abstract Aim PIONEER REAL Saudi Arabia investigated real‐world clinical outcomes associated with the use of once‐daily oral semaglutide in adults with type 2 diabetes (T2D). Materials and Methods This was a 34‐ to 44‐week multicentre, prospective, open‐label study in adults with T2D, who were treatment‐naive to injectable glucose‐lowering medication ...
Hussein ElBadawi +11 more
wiley +1 more source
Diabetes, Metabolic Syndrome and Obesity, 2014 Binayak Sinha,1 Kalyan Kumar Gangopadhyay,2 Samit Ghosal31Department of Endocrinology, AMRI Hospital, 2Department of Endocrinology, Fortis and Peerless Hospital, 3Nightingale Hospital, Kolkata, IndiaAbstract: Insulin therapy is not without side effects ...
Sinha B, Gangopadhyay KK, Ghosal S
doaj
Inpatient glycemic variability and long-term mortality in hospitalized patients with type 2 diabetes [PDF]
, 2016 Aims/Hypothesis: To determine the association between inpatient glycemic variability and long-term mortality in patients with type 2 diabetes mellitus. Methods: Capillary blood glucose (CBG) of inpatients from 8 hospitals was analysed.
Cunningham, Scott G. +3 more
core +2 more sources
Low immunogenicity of insulin efsitora alfa in participants with type 1 and type 2 diabetes mellitus
Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1350-1358, February 2026.Abstract Aims To evaluate treatment‐emergent antidrug antibodies (TE ADA) in once‐weekly basal insulin efsitora‐treated participants with type 1 and type 2 diabetes mellitus (T1DM and T2DM) from 5 phase 3 clinical trials and their potential impact on pharmacokinetics, efficacy and safety.
Yun Wang +8 more
wiley +1 more source